

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference INGN : 120WO	FOR FURTHER ACTION see Form PCT/ISA/220 as well as, where applicable, item 5 below.	
International application No. PCT/US2005/006108	International filing date (day/month/year) 24/02/2005	(Earliest) Priority Date (day/month/year) 24/02/2004
Applicant INTROGEN THERAPEUTICS, INC.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ The international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. ☐ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☒ **Certain claims were found unsearchable** (See Box II).

3. ☐ **Unity of invention is lacking** (see Box III).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

COMBINATION OF AD-P53 AND CHEMOTHERAPY FOR THE TREATMENT OF TUMOURS

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

a. the figure of the **drawings** to be published with the abstract is Figure No. _____

☐ as suggested by the applicant.

☐ as selected by this Authority, because the applicant failed to suggest a figure.

☐ as selected by this Authority, because this figure better characterizes the invention.

b. ☒ none of the figures is to be published with the abstract.

INTERNATIONAL SEARCHREPORT

International Application No

PCT/US2005/006108

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K48/00 A61K38/17 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NEMUNAITIS J ET AL: "Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer"</p> <p>JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 3, February 2000 (2000-02), pages 609-622, XP002331130</p> <p>ISSN: 0732-183X</p> <p>page 610, left-hand column, paragraph 5 - right-hand column, paragraph 1</p> <p>page 611, left-hand column, paragraph 2</p> <p>page 612, right-hand column, paragraph 5</p> <p>page 609</p> <p>abstract</p> <p>-----</p> <p>-/--</p>	1-30

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

22 June 2005

Date of mailing of the international search report

04/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2005/006108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BULLER RICHARD E ET AL: "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500" CANCER GENE THERAPY, vol. 9, no. 7, July 2002 (2002-07), pages 567-572, XP002331131 ISSN: 0929-1903 page 568, left-hand column, paragraph 1 - page 569, left-hand column, paragraph 1 -----	1-30
X	DATABASE BIOSIS 'Online!' BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, PIROLLO KATHLEEN F ET AL: "P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy" XP002331134 Database accession no. PREV199799548911 abstract & ONCOGENE, vol. 14, no. 14, 1997, pages 1735-1746, ISSN: 0950-9232 -----	1-35
X	DATABASE BIOSIS 'Online!' BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CHANG ESTHER H ET AL: "Restoration of the G-1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy" XP002331135 Database accession no. PREV199799596956 abstract & ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, vol. 123, no. 5, 1997, pages 507-512, ISSN: 0886-4470 ----- -/--	1-35

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US2005/006108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GURNANI MAYA ET AL: "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer"</p> <p>CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 44, no. 2, August 1999 (1999-08), pages 143-151, XP002331132</p> <p>ISSN: 0344-5704</p> <p>page 143</p> <p>abstract</p> <p>page 144, right-hand column, paragraph 1</p> <p>page 145, right-hand column, paragraph 4</p> <p>page 147, right-hand column, paragraph 4 -</p> <p>page 148, right-hand column, paragraph 1</p> <p>page 149</p>	1-35
X	<p>-----</p> <p>NIELSEN L L ET AL: "ADENOVIRUS-MEDIATED P53 GENE THERAPY AND PACLITAXEL HAVE SYNERGISTIC EFFICACY IN MODELS OF HUMAN HEAD AND NECK, OVARIAN, PROSTATE AND BREAST CANCER"</p> <p>CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, no. 4, April 1998 (1998-04), pages 835-846, XP002331133</p> <p>ISSN: 1078-0432</p> <p>page 835</p> <p>abstract</p> <p>page 837, left-hand column, last paragraph - right-hand column, paragraph 1</p> <p>page 843; figures 6,7</p>	1-35
X	<p>-----</p> <p>ALEXANDER W A ET AL: "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 596, XP001206623</p> <p>& 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999</p> <p>ISSN: 0197-016X</p> <p>abstract #3930</p> <p>-----</p>	1-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/006108

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/006108

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K48/00 A61K38/17 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>NEMUNAITIS J ET AL: "Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer"</p> <p>JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 3, February 2000 (2000-02), pages 609-622, XP002331130</p> <p>ISSN: 0732-183X</p> <p>page 610, left-hand column, paragraph 5 - right-hand column, paragraph 1</p> <p>page 611, left-hand column, paragraph 2</p> <p>page 612, right-hand column, paragraph 5</p> <p>page 609</p> <p>abstract</p> <p style="text-align: center;">----- -/-</p>	1-30

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

22 June 2005

Date of mailing of the international search report

04/08/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sitch, W

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/006108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>BULLER RICHARD E ET AL: "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500" CANCER GENE THERAPY, vol. 9, no. 7, July 2002 (2002-07), pages 567-572, XP002331131 ISSN: 0929-1903 page 568, left-hand column, paragraph 1 - page 569, left-hand column, paragraph 1</p>	1-30
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, PIROLLO KATHLEEN F ET AL: "P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy" XP002331134 Database accession no. PREV199799548911 abstract & ONCOGENE, vol. 14, no. 14, 1997, pages 1735-1746, ISSN: 0950-9232</p>	1-35
X	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CHANG ESTHER H ET AL: "Restoration of the G-1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy" XP002331135 Database accession no. PREV199799596956 abstract & ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, vol. 123, no. 5, 1997, pages 507-512, ISSN: 0886-4470</p>	1-35

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US2005/006108

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>GURNANI MAYA ET AL: "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer"</p> <p>CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 44, no. 2, August 1999 (1999-08), pages 143-151, XP002331132 ISSN: 0344-5704 page 143 abstract page 144, right-hand column, paragraph 1 page 145, right-hand column, paragraph 4 page 147, right-hand column, paragraph 4 - page 148, right-hand column, paragraph 1 page 149</p> <p>-----</p>	1-35
X	<p>NIELSEN L L ET AL: "ADENOVIRUS-MEDIATED P53 GENE THERAPY AND PACLITAXEL HAVE SYNERGISTIC EFFICACY IN MODELS OF HUMAN HEAD AND NECK, OVARIAN, PROSTATE AND BREAST CANCER"</p> <p>CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, no. 4, April 1998 (1998-04), pages 835-846, XP002331133 ISSN: 1078-0432 page 835 abstract page 837, left-hand column, last paragraph - right-hand column, paragraph 1 page 843; figures 6,7</p> <p>-----</p>	1-35
X	<p>ALEXANDER W A ET AL: "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy"</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 596, XP001206623 & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999 ISSN: 0197-016X abstract #3930</p> <p>-----</p>	1-35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2005/006108

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.